中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 5
May  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(5): 989-996

Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism

DOI: 10.12449/JCH240519
  • 1.

    College of Clinical Medicine，Guizhou Medical University，Guiyang 550000，China

  • 2.

    Department of Hepatobiliary Surgery，The Affiliated Baiyun Hospital of Guizhou Medical University，Guiyang 550000，China

  • 3.

    Department of Hepatobiliary Surgery，The Affiliated Hospital of Guizhou Medical University，Guiyang 550000，China

  • 4.

    Department of Hepatobiliary Surgery，The Affiliated Cancer Hospital of Guizhou Medical University，Guiyang 550000，China

Research funding:

National Natural Science Foundation of China (81960431);

National Natural Science Foundation of China (81960535);

Science and Technology Fund of Guizhou Province (QKHZC［2021］YB444)

More Information
  • Corresponding author: PAN Yaozhen， panyaozhen@gmc.edu.cn （ORCID： 0000-0002-9300-382X）
  • Received Date: 2023-10-13
  • Accepted Date: 2023-11-17
  • Published Date: 2024-05-25
    Abstract
  •   Objective  To investigate the effect of ankyrin-repeat domain-containing protein 22 （ANKRD22） on the proliferation， invasion， and migration of human hepatoma cells and its molecular mechanism.  Methods  The TCGA database was used to analyze the expression level of ANKRD22 in normal liver tissue and hepatocellular carcinoma tissue and its association with prognosis. Western Blot and qRT-PCR were used to measure the expression of ANKRD22 in human normal liver cells （L-02） and human hepatoma cells （Huh7， HepG2， MHCC-97H， SK-HEP-1， and SMMC-7721）； CCK-8 assay， EdU， wound healing assay， and Transwell assay were used to observe the effect of ANKRD22 on the proliferation， invasion， and migration of hepatoma cells； Western Blot was used to investigate the association of ANKRD22 with cyclins and EMT-related proteins； KEGG and ssGSEA analyses were performed to investigate the mechanism of action of ANKRD22 in hepatoma cells， and related experiments were conducted for validation. The independent-samples t-test was used for comparison of continuous data between two groups； a one-way analysis of variance was used for comparison between multiple groups， and the least significant difference t-test was used for further comparison between two groups.  Results  In the TCGA database， the expression level of ANKRD22 in hepatoma tissue was significantly higher than that in normal liver tissue （t=5.083， P<0.05）， and the patients with a high expression level of ANKRD22 had longer overall survival and disease-related survival than those with a low expression level of ANKRD22 （P<0.05）. The expression level of ANKRD22 in various human hepatoma cell lines was higher than that in human normal liver cells （all P<0.05）. Cell proliferation assay showed that the ANKRD22 overexpression group had significantly higher EdU positive rate and proliferation rate than the Vector group （t=19.60 and 6.72， both P<0.001）， and compared with the si-NC group， the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower EdU positive rate and proliferation rate （all P<0.001）. Compared with the Vector group， the overexpression group had significantly higher expression levels of Cyclin E1， Cyclin D1， CDK7， and CDK4 （t=3.54， 4.95， 6.34， and 5.19， all P<0.01）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower expression levels than the si-NC group （all P<0.001）. The overexpression group had a significantly lower expression level of P27 than the Vector group （t=6.12， P<0.001）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had a significantly higher expression level than the si-NC group （both P<0.001）. Invasion and migration experiments showed that compared with the Vector group， the ANKRD22 overexpression group had significantly higher migration rate and number of crossings through the membrane （migration group and invasion group） （t=5.01， 25.60， and 3.67， all P<0.05）， and compared with the si-NC group， thesi-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower migration rate and number of crossings through the membrane （migration group and invasion group） （all P<0.01）. The overexpression group had significantly higher expression levels of N-cadherin， Vimentin， and Snail than the Vector group （t=12.13， 8.85， and 13.97， all P<0.001）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower expression levels than the si-NC group （all P<0.001）； the overexpression group had a significantly lower expression level of E-cadherin than the Vector group （t=4.98， P<0.01）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had a significantly higher expression level than the si-NC group （both P<0.001）. The KEGG enrichment analysis and the ssGSEA analysis showed that ANKRD22 was associated with the PI3K/AKT/mTOR signaling pathway in hepatocellular carcinoma， and the overexpression group had significantly higher expression levels of p-AKT/AKT， p-PI3K/PI3K， and p-mTOR/mTOR than the Vector group （t=12.21， 3.43， and 9.75， all P<0.01）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower expression levels than the si-NC group （all P<0.001）.  Conclusion  ANKRD22 is highly expressed in hepatoma cells and can promote the proliferation， invasion， and migration of hepatoma cells and the activation of the PI3K/AKT/mTOR signaling pathway.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 6. DOI: 10.1038/s41572-020-00240-3.
    [2]
    FOGLIA B, TURATO C, CANNITO S. Hepatocellular carcinoma: Latest research in pathogenesis, detection and treatment[J]. Int J Mol Sci, 2023, 24( 15): 12224. DOI: 10.3390/ijms241512224.
    [3]
    DING CM, HOU JF, TAO GW, et al. Early diagnosis and screening of hepatocellular carcinoma[J/OL]. Chin J Hepatic Surg Electron Ed, 2023, 12( 1): 22- 28. DOI: 10.3877/cma.j.issn.2095-3232.2023.01.005.

    丁成明, 侯嘉丰, 陶光伟, 等. 肝细胞癌早期诊断和筛查[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12( 1): 22- 28. DOI: 10.3877/cma.j.issn.2095-3232.2023.01.005.
    [4]
    KIM E, VIATOUR P. Hepatocellular carcinoma: Old friends and new tricks[J]. Exp Mol Med, 2020, 52( 12): 1898- 1907. DOI: 10.1038/s12276-020-00527-1.
    [5]
    LIU XF, ZHANG J, YAO L, et al. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. J Clin Hepatol, 2022, 38( 5): 992- 997. DOI: 10.3969/j.issn.1001-5256.2022.05.004.

    刘秀峰, 张珏, 姚琳, 等. 中晚期肝细胞癌靶向联合免疫治疗进展[J]. 临床肝胆病杂志, 2022, 38( 5): 992- 997. DOI: 10.3969/j.issn.1001-5256.2022.05.004.
    [6]
    YANG SS. Evaluation of Clinical Significance of ANKRD22 in Colorectal Cancer[D]. Hangzhou: Zhejiang University, 2019. DOI: 10.27461/d.cnki.gzjdx.2019.001668.

    杨赛赛. ANKRD22在结直肠癌细胞中表达意义的研究[D]. 杭州: 浙江大学, 2019. DOI: 10.27461/d.cnki.gzjdx.2019.001668
    [7]
    UTSUMI T, HOSOKAWA T, SHICHITA M, et al. ANKRD22 is an N-myristoylated hairpin-like monotopic membrane protein specifically localized to lipid droplets[J]. Sci Rep, 2021, 11( 1): 19233. DOI: 10.1038/s41598-021-98486-8.
    [8]
    WANG R, WU YH, ZHU Y, et al. ANKRD22 is a novel therapeutic target for gastric mucosal injury[J]. Biomed Pharmacother, 2022, 147: 112649. DOI: 10.1016/j.biopha.2022.112649.
    [9]
    ZHOU HN, LI YM. Conversion therapy for hepatocellular carcinoma[J/OL]. Chin J Hepatic Surg Electron Ed, 2022, 11( 6): 542- 547. DOI: 10.3877/cma.j.issn.2095-3232.2022.06.002.

    周辉年, 李玉民. 肝癌转化治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2022, 11( 6): 542- 547. DOI: 10.3877/cma.j.issn.2095-3232.2022.06.002.
    [10]
    LU SL, YAO JN, YUAN GD, et al. Current status and prospect of clinical and basic research on conversion therapy for hepatocellular carcinoma[J]. Chin J Exp Surg, 2022, 39( 10): 1837- 1843. DOI: 10.3760/cma.j.cn421213-20220210-01043.

    陆世鎏, 姚建妮, 袁观斗, 等. 肝癌转化治疗临床与基础研究现状与展望[J]. 中华实验外科杂志, 2022, 39( 10): 1837- 1843. DOI: 10.3760/cma.j.cn421213-20220210-01043.
    [11]
    PARRA RG, ESPADA R, VERSTRAETE N, et al. Structural and energetic characterization of the ankyrin repeat protein family[J]. PLoS Comput Biol, 2015, 11( 12): e1004659. DOI: 10.1371/journal.pcbi.1004659.
    [12]
    LIU X, ZHAO JL, WU Q, et al. ANKRD22 promotes glioma proliferation, migration, invasion, and epithelial-mesenchymal transition by upregulating E2F1-mediated MELK expression[J]. J Neuropathol Exp Neurol, 2023, 82( 7): 631- 640. DOI: 10.1093/jnen/nlad034.
    [13]
    WU YG, LIU HX, GONG YF, et al. ANKRD22 enhances breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression[J]. Bosn J Basic Med Sci, 2021, 21( 3): 294- 304. DOI: 10.17305/bjbms.2020.4701.
    [14]
    YIN J, FU WF, DAI L, et al. ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1[J]. Sci Rep, 2017, 7( 1): 4430. DOI: 10.1038/s41598-017-04818-y.
    [15]
    WU YG, CHEN WX, ZHANG B, et al. ANKRD22 knockdown suppresses papillary thyroid cell carcinoma growth and migration and modulates the Wnt/β-catenin signaling pathway[J]. Tissue Cell, 2023, 84: 102193. DOI: 10.1016/j.tice.2023.102193.
    [16]
    PAN TH, LIU JW, XU S, et al. ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells[J]. Theranostics, 2020, 10( 2): 516- 536. DOI: 10.7150/thno.37472.
    [17]
    CHEN HH, YANG KQ, PANG LX, et al. ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer[J]. J Immunother Cancer, 2023, 11( 2): e005527. DOI: 10.1136/jitc-2022-005527.
    [18]
    QIU YQ, YANG SS, PAN TH, et al. ANKRD22 is involved in the progression of prostate cancer[J]. Oncol Lett, 2019, 18( 4): 4106- 4113. DOI: 10.3892/ol.2019.10738.
    [19]
    TIAN LY, SMIT DJ, JÜCKER M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism[J]. Int J Mol Sci, 2023, 24( 3): 2652. DOI: 10.3390/ijms24032652.
    [20]
    LI YH, YIN YL, HE Y, et al. SOS1 regulates HCC cell epithelial-mesenchymal transition via the PI3K/AKT/mTOR pathway[J]. Biochem Biophys Res Commun, 2022, 637: 161- 169. DOI: 10.1016/j.bbrc.2022.11.015.
    [21]
    CHEN JX, CHEN JD, HUANG JX, et al. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway[J]. Aging(Albany NY), 2019, 11( 23): 10839- 10860. DOI: 10.18632/aging.102488.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (169) PDF downloads(20) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return